Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

27.05.16		IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Combined Shareholders’ Meeting to Be Held on 31 May 2016 (Businesswire)
10.05.16		Ipsen: Combined Shareholders’ Meeting of 31 May 2016 (Businesswire)
10.05.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.05.16		Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen’s Paris-Saclay Campus (Businesswire)
28.04.16		Ipsen’s First Quarter 2016 Sales (Businesswire)
26.04.16		Probi and Ipsen Sign Extensive Primary Care Distribution Agreement for Probiotic LP299V®, Lactobacillus plantarum 299v (Businesswire)
08.04.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
05.04.16		Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery (Businesswire)
31.03.16		The Ipsen Group Publishes Its 2015 Registration Document (Businesswire)
07.03.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.03.16		Ipsen: Information Relating to the Compensation of Executive Directors (Businesswire)
01.03.16		Ipsen’s 2015 Results and 2016 Financial Objectives (Businesswire)
01.03.16		Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan (Businesswire)
29.02.16		Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan (Businesswire)
22.02.16		IPSEN: Information Relating to the Conditions of Termination of Mrs. Christel Bories' Corporate Duties (Businesswire)
16.02.16		Changes to Ipsen Corporate Governance (Businesswire)
08.02.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.01.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.01.16		Half-Year IPSEN Liquidity Contract Statement Entered into With NATIXIS (Businesswire)
06.01.16		Ipsen and Galderma Expand Current Distribution Agreement for Dysport® in Aesthetic Indications to Some Key Asia-Pacific Territories1 (Businesswire)
04.01.16		IPSEN: Disclosure of Transactions in Own Shares on 28/12/2015 (Businesswire)
04.01.16		Ipsen: Disclosure of Transactions in Own Shares Between 21/12/2015 and 24/12/2015 (Businesswire)
22.12.15		IPSEN: Disclosure of Transactions in Own Shares between 14/12/2015 and 18/12/2015 (Businesswire)
17.12.15		Ipsen Announces Its Corporate Agenda for 2016 (Businesswire)
15.12.15		Ipsen: Disclosure of Transactions in Own Shares between 07/12/2015 and 11/12/2015 (Businesswire)
08.12.15		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.12.15		IPSEN: Disclosure of Transactions in Own Shares between 30/11/2015 and 04/12/2015 (Businesswire)
30.11.15		IPSEN: Disclosure of transactions in own shares between 23/11/2015 and 27/11/2015 (Businesswire)
23.11.15		IPSEN: Disclosure of transactions in own shares between 16/11/2015 and 20/11/2015 (Businesswire)
19.11.15		Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology (Businesswire)
16.11.15		IPSEN: Disclosure of transactions in own shares between 09/11/2015 and 13/11/2015 (Businesswire)
09.11.15		IPSEN: Disclosure of transactions in own shares between 02/11/2015 and 06/11/2015 (Businesswire)
06.11.15		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
02.11.15		IPSEN: Disclosure of Transactions in Own Shares between 26/10/2015 and 30/10/2015 (Businesswire)
29.10.15		Ipsen: sales in the 3rd quarter and first nine months of 2015 (Businesswire)
28.10.15		Telesta Therapeutics and Ipsen Announce Exclusive License Agreement for MCNA1 for the Treatment of Non-Muscle Invasive Bladder Cancer in Major Ex-United States Territories (Businesswire)
26.10.15		IPSEN: Disclosure of Transactions in Own Shares between 19/10/2015 and 23/10/2015 (Businesswire)
26.10.15		Ipsen and EpiVax collaborate to produce next generation botulinum toxins (Businesswire)
19.10.15		IPSEN: Disclosure of Transactions in Own Shares Between 12/10/2015 and 16/10/2015 (Businesswire)
12.10.15		IPSEN: Disclosure of Transactions in Own Shares Between 05/10/2015 and 09/10/2015 (Businesswire)
08.10.15		IPSEN S.A.: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
05.10.15		IPSEN: Disclosure of Transactions in Own Shares between 28/09/2015 and 02/10/2015 (Businesswire)
01.10.15		Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen (Businesswire)
01.10.15		Ipsen Announces Release of an Additional Batch of Increlex® in the U.S. (Businesswire)
28.09.15		IPSEN: Disclosure of Transactions in Own Shares Between 21/09/2015 and 25/09/2015 (Businesswire)
21.09.15		IPSEN: Disclosure of transactions in own shares between 14/09/2015 and 18/09/2015 (Businesswire)
14.09.15		IPSEN: Disclosure of Transactions in Own Shares between 07/09/2015 and 11/09/2015 (Businesswire)
10.09.15		Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
07.09.15		IPSEN: Disclosure of transactions in own shares between 31/08/2015 and 04/09/2015 (Businesswire)
31.08.15		IPSEN: Disclosure of Transactions in Own Shares Between 24/08/2015 and 28/08/2015 (Businesswire)

Erste Seite Zurück | ... | 4 | 5 | 6 | 7 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 16:35
Kaufwert:	EUR
	Hinzufügen Speichern